Health Trials

About this trial

The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.

Eligibility criteria

Qualifiers

Aged 18-75 years old and of either sex；

Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;

Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.

Disqualifiers

Pregnancy；

Severe hepatic and renal insufficiency;

History of serious surgery in the last month;

Allergic to antibody or single-domain antibody radiopharmaceuticals.

Trial design

Treatments tested in this trial

  • [68Ga]Ga-DOTA-H2D3
  • [18F]F-RESCA-RB14
  • [68Ga]Ga-NOTA-T4
  • [18F]F-RESCA-T4
  • [68Ga]Ga-NOTA-G5
  • [18F]F-RESCA-G5
  • [68Ga]Ga-NOTA-WWH347
  • [18F]F-RESCA-WWH347
  • [68Ga]Ga-NOTA-RND20
  • [18F]F-RESCA-RND20

Treatment groups

400 Participants
are divided into 1 treatment group

Locations

1
Renji Hospital, School of Medicine, Shanghai Jiao Tong University200127, ShanghaiShanghai Municipality, China

Sponsors and collaborators

RenJi Hospital

Lead sponsor

Source ClinicalTrials.gov